Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Marco Del Chiaro MD, PhD, FACS

Marco Del Chiaro MD, PhD, FACS

Professor and Division Chief of Surgical Oncology; Morton and Sandra Saffer Endowed Chair; Director, University of Colorado HPB Program; Director, University of Colorado NPF Designated Center of Excellence for Pancreatic Cancer, Department of Surgery, University of Colorado School of Medicine; Cancer Center, University of Colorado School of Medicine, Aurora, Colorado

Dr. Del Chiaro is Professor of Surgery and Division Chief of Surgical Oncology at the University of Colorado Anschutz Medical Campus. He is an academic surgical oncologist specializing in pancreatic disease. He is internationally recognized as a leader in the surgical treatment of borderline resectable/locally advanced pancreatic cancer and treatment of precursor lesions of pancreatic cancer. He is the PI of the evidence-based European guidelines on pancreatic cystic tumors.


Dr. Del Chiaro discloses receiving an industry grant (Haemonetics, Inc) to conduct a multicenter study to evaluate the prognostic implications of TEG in pancreatic cancer and being co-principal investigator of a Boston Scientific sponsored international multicenter study on the use of intraoperative pancreatoscopy of patients with IPMN.